Advancing the Treatment of Patients with Myelofibrosis

To participate in this activity, please:

Myelofibrosis, a rare chronic myeloproliferative neoplasm disorder, is often an overlooked disease due to its rarity and underappreciation of the severity of clinical manifestations and burden of disease. This has led to multiple gaps in knowledge and understanding of the management of patients with myelofibrosis, especially the more severe or higher-risk forms. Drs. Aaron Gerds and Michael Grunwald discuss the current challenges that exist across the myelofibrosis landscape, including burden of disease, molecular abnormalities, pharmacologic options, and emerging novel therapies. Case studies are discussed to facilitate integration of key concepts into clinical practice.

Course Credit:

1 ACPE Contact Hour
1 AMA PRA Category 1 CreditTM
1 ANCC Contact Hour
1 CA-BRN Contact Hour
0.5 Pharmacology Hours


Opens: 2023-04-30
Closes: 2024-04-30

Target Audience:

Hematologists, hematologist-oncologists, hematology advanced practitioners, hematology nurses, pharmacists, and other clinicians who diagnose or treat patients with myelofibrosis.

This educational activity is supported by an educational grant from GSK.

    Presenting Faculty

  • Aaron T. Gerds, MD, MS

    Associate Professor of Medicine
    Hematology & Medical Oncology
    Deputy Director for Clinical Research
    Cleveland Clinic Taussig Cancer Institute
    Medical Director
    Case Comprehensive Cancer Center Clinical Research Office
    Principal Investigator
    Case Lead Academic Participating Site
    Cleveland, Ohio

  • Michael R. Grunwald, MD

    Chief, Leukemia Division
    Director, Transplantation and Cellular Therapy Program
    Department of Hematologic Oncology and Blood Disorders
    Levine Cancer Institute
    Charlotte, North Carolina